Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.